Panel Titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine”
SAN FRANCISCO, January 10, 2014 – Invitae Corporation, a genetic diagnostics company, today announced that Sean George, co-founder of Invitae, is scheduled to speak on a panel titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine” during the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 at 5:00 pm PST in San Francisco.
A live, listen-only webcast of the presentation can be accessed by visiting http://jpmorgan.metameetings.com/confbook/healthcare14/directlink?p=14095.
About Invitae Corporation
Invitae's mission is to reinvent genetic testing by making it more affordable and accessible than ever before. Invitae hopes to lead the way from an era of genetic scarcity to genetic abundance to significantly improve healthcare worldwide. Specializing in genetic diagnostics for hereditary disorders, the company is pursuing a strategy over the next several years to aggregate all the world's medical genetic tests (>3,000 known Mendelian inherited conditions) into a single assay at a lower cost than most single gene tests today. This capability is increasingly enabled by the rapid advancements in DNA sequencing technology. Invitae has raised $87 million from investors, including Thomas McNerney Partners, Casdin Capital, Genesys Capital, Genomic Health, Inc. (NASDAQ: GHDX), Redmile Group, and Randy Scott. For further information, please visit www.invitae.com.